

Injectable silicone biomaterial (PTQTM) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence: a randomised trial

Submission date 22/05/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/06/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/06/2008	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Miranda Chan

Contact details

Caritas Medical Centre, 111
Wing Hong Street
Shum Shui Po
Hong Kong
Hong Kong

-
+852 3408 7785
mirchan@hotmail.com

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Study objectives

To compare safety and efficacy of PTQTM compared with Durasphere® in treating patients with passive faecal incontinence.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Human Resource Ethics Committee of Epworth Hospital

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Passive faecal incontinence

Interventions

Injectable bulking agents to augment the bulk of the internal anal sphincter: injectable silicone biomaterial (PTQTM) vs carbon-coated beads (Durasphere®).

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

PTQTM, Durasphere®

Primary outcome(s)

Wexners continence score, assessed at 2 and 6 weeks, then 6 and 12 months after treatment

Key secondary outcome(s)

The following were assessed at 2 and 6 weeks, then 6 and 12 months after treatment:

1. Faecal incontinence quality of life (FIQL) scale
2. Short Form 12 (SF-12) health survey questionnaire
3. Adverse events

Completion date

31/10/2006

Eligibility

Key inclusion criteria

1. Both males and females, no age limits
2. Faecal seepage or soiling for more than twice a week caused by internal sphincter (IAS) dysfunction
3. Not responding to treatment with dedicated pelvic floor exercises and stool bulking agents

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Other

Sex

All

Key exclusion criteria

1. Perianal sepsis
2. Anorectal cancer
3. Immunosuppression
4. Rectal prolapse
5. Inflammatory bowel disease
6. Congenital anorectal malformation
7. Neurological disorders such as Parkinsons disease
8. Multiple sclerosis
9. Spinal-cord injury
10. Stoma in situ
11. Pregnancy
12. External anal sphincter defect of more than 120° of the circumference
13. Bleeding diathesis,
14. Mental or physical disability precluding adherence to study protocol

Date of first enrolment

01/08/2005

Date of final enrolment

31/10/2006

Locations

Countries of recruitment

Australia

Hong Kong

Study participating centre
Caritas Medical Centre, 111
Hong Kong
Hong Kong
-

Sponsor information

Organisation
Epworth Hospital, University of Melbourne (Australia)

ROR
<https://ror.org/01ej9dk98>

Funder(s)

Funder type
Not defined

Funder Name
Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration